ArticleCancers2021
The Vulvar Immunohistochemical Panel (VIP) Project: Molecular Profiles of Vulvar Squamous Cell Carcinoma.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Positivity Rate of PD-L1 Expression and Its Clinical Significance in Vulvar Cancer: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Efficacy of pembrolizumab in advanced cancer of the vulva: a systematic review and single-arm meta-analysis.Frontiers in oncology · 2024Pooled it
- Integration of L1CAM and β-catenin immunohistochemistry for prognostic risk stratification of endometrial carcinoma: a practical approach for resource-limited settings.Medical molecular morphology · 2026Article
- Evaluation of HER2 and Nectin-4 Expression in Primary Vaginal Cancers.International journal of molecular sciences · 2026Article
- HER2 Expression in Squamous Cell Carcinoma of the Vulva: A Systematic Review and Meta-Analysis.Cancers · 2026Review
- Risk stratification of groin node metastases in vulvar cancer biopsies based on histology and immunohistochemical staining.Journal of gynecologic oncology · 2026Article
- Endometrial carcinomas with solid basaloid morphology and geographic necrosis: clinicopathological and molecular features of 18 cases.Virchows Archiv : an international journal of pathology · 2026Article
- Systemic inflammation indices and serum squamous cell carcinoma (SCC) antigen: an exploratory analysis on prognosis of patients with vulvar squamous cell carcinoma.Gynecologic oncology reports · 2026Article
- Local carboxymethyl β-glucan and polycarbophil in women positive for human papillomavirus: a prospective observational study.Drugs in context · 2026Article
- Review
- Ki-67 as a Prognostic Marker in Squamous Cell Carcinomas of the Vulva: A Systematic Review.Journal of clinical medicine · 2025Review
- Development and validation of a prognosis prediction model for overall survival in correlation between butyrate metabolism and gastric cancer prognosis: Mendelian randomization and transcriptomics analysis.Translational cancer research · 2025Article
- Utilization of immunohistochemistry in gynecologic tumors: An expert review.Gynecologic oncology reports · 2024Review
- A contemporary view on vascular resections and reconstruction during hepatectomies.Updates in surgery · 2024Review
- Review
- Factors associated with vulvar cancer from 2005 to 2021 in Togo, sub-Saharan Africa.BMC women's health · 2023Article
- An integrated model for prognosis in vulvar squamous cell carcinoma.BMC cancer · 2023Article
- Review
- How SARS-CoV-2 Infection Impacts the Management of Patients with Vulvar Cancer: Experience in a Third-Level Hospital of Southern Italy.Journal of personalized medicine · 2023Article
- Secondary post-oncologic vulvar reconstruction - a simplified algorithm.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe study's aim was to investigate the immunohistochemical (IHC) expression of biological markers as potential prognostic/therapeutic factors in vulvar squamous cell carcinoma (VSCC). METHODOLOGY: A series of 101 patients surgically treated at our center from 2016 to 2020 were retrospectively enrolled: 53 node-negative (Group A) and 48 node-positive (Group B). A total of 146 samples, 101 from primary tumor (T) and 45 from nodal metastases (N), were investigated. The IHC panel included: p16, p53, MLH1, MSH2, MSH6, PMS2, PD-L1, CD3, HER2/neu, ER, PR, EGFR, VEGF, and CD31. The reactions were evaluated on qualitative and semi-quantitative scales. Generalized Linear Model (GLM) and cluster analysis were performed in R statistical environment. A distance plot compared the IHC panel of T with the correspondent N.
resultsIn Group A: p16-positive expression (surrogate of HPV-dependent pathway) was significantly higher (20.8% vs. 6.2%,
conclusionsOur results support a potential role of immune checkpoint inhibitors and anti-VEGF and anti-EGFR drugs especially in patients with worse prognosis (metastatic, HPV-independent). A panel including EGFR, VEGF, PDL1, p16, and p53 might be performed routinely in primary tumor and repeated in case of lymph node metastases to identify changes in marker expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.